#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This dose-finding trial provides clinicians with much-needed evidence on optimal THC dosing for anxiety and stress, conditions for which cannabis is increasingly requested by patients but lacks clear clinical dosing guidelines. The standardized, controlled nature of this research using pharmaceutical-grade capsules helps establish whether THC has genuine therapeutic benefit for these psychiatric symptoms or if effects are primarily placebo-driven. Results could inform clinical practice by establishing safe and effective dosing ranges, reducing current prescribing uncertainty and improving patient outcomes.
Avicanna is sponsoring a randomized controlled trial at the University of Calgary to investigate dose-dependent effects of oral THC on anxiety and stress symptoms using the company’s proprietary capsule formulation. This study addresses a significant clinical gap, as evidence-based dosing guidance for THC in anxiety disorders remains limited despite increasing patient interest in cannabis-based treatments. The trial’s focus on standardized oral capsules rather than variable plant material or smokable products will help establish more reliable dose-response relationships applicable to clinical practice. Results from this dose-finding study could inform clinicians about optimal THC dosing strategies, potential safety thresholds, and patient population characteristics most likely to benefit from this intervention. For clinicians considering cannabis as a therapeutic option for anxiety-prone patients, evidence from this trial may eventually provide the rigorous dosing data necessary to make informed prescribing decisions rather than relying on anecdotal patient reports or extrapolation from other conditions. Clinicians should monitor the publication of this trial’s results as they may substantially improve the ability to offer THC-based treatments with predictable clinical outcomes.
“We need dose-finding studies like this one because prescribing THC for anxiety remains more art than science in most practices, and that’s a liability for both patients and physicians. The challenge is that oral THC’s effects are highly variable based on individual metabolism and cannabinoid sensitivity, so establishing reliable dosing protocols through rigorous RCTs is exactly what will move us from anecdotal practice to evidence-based medicine.”
? While industry-sponsored dose-finding studies can provide valuable pharmacokinetic and efficacy data, clinicians should recognize that manufacturer involvement may introduce bias in study design, outcome selection, or dissemination of results. The promise of identifying optimal THC dosing for anxiety is clinically relevant given the increasing patient interest in cannabis for this indication, yet the evidence base remains limited and heterogeneous, with prior studies showing inconsistent anxiolytic effects depending on dose, route, individual factors, and baseline anxiety severity. It is important to note that THC’s dose-response relationship is not linear and may follow an inverted U-shaped curve, meaning higher doses do not necessarily confer greater benefit and may paradoxically increase anxiety in some populations. When this trial’s results are published, clinicians should evaluate the methodological rigor, generalizability of the study population, and whether findings align with or diverge from independent research before incorporating dose recommendations into
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
